Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter November 12, 2020

The utility of 68Ga-DOTATATE PET/CT in localizing primary/metastatic pheochromocytoma and paraganglioma in children and adolescents – a single-center experience

Sanjeet Kumar Jaiswal ORCID logo, Vijaya Sarathi, Gaurav Malhotra, Priya Hira, Ravikumar Shah, Virendra A. Patil, Abhay Dalvi, Gagan Prakash, Anurag R. Lila, Nalini S. Shah and Tushar Bandgar ORCID logo



Pediatric pheochromocytoma and paraganglioma (PPGL) are rare tumors with limited data on the diagnostic performance of 68Ga-DOTA(0)-Tyr(3)-octreotate positron emission tomography–computed tomography (68Ga-DOTATATE PET/CT). We have described our experience of 68Ga-DOTATATE PET/CT in overall and von Hippel Lindau (VHL)-associated pediatric PPGL and compared its sensitivity with that of 131I-meta-iodobenzyl-guanidine (131I-MIBG), 18F-fluorodeoxyglucose PET/CT (18F-FDG PET/CT), and contrast-enhanced CT (CECT).


Retrospective evaluation of consecutive PPGL patients (age: ≤20 years), who had undergone at least one functional imaging [131I-MIBG, 18F-FDG PET/CT, and/or 68Ga-DOTATATE PET/CT], was done. Composite of anatomical and all the performed functional imaging scans, image comparator (IC), was considered as the gold standard for sensitivity analysis.


In a cohort of 32 patients (16 males, age at diagnosis: 16.4 ± 2.68 years), lesion-wise sensitivity of 68Ga-DOTATATE PET/CT (95%) was higher than that of both 18F-FDG-PET/CT (80%, p=0.027) and 131I-MIBG (65%, p=0.0004) for overall lesions, than that of 18F-FDG-PET/CT (100 vs. 67%, p=0.017) for primary PPG, and than that of 131I-MIBG (93 vs. 42%, p=0.0001) for metastases. In the VHL (n=14), subgroup, 68Ga-DOTATATE PET/CT had higher lesion-wise sensitivity (100%) compared to 18F-FDG PET/CT (74%, p=0.045) and 131I-MIBG (64%, p=0.0145).


In our pediatric PPGL cohort, overall lesion-wise sensitivity of 68Ga-DOTATATE PET/CT was higher than that of 18F–FDG PET/CT and 131I-MIBG scintigraphy. Hence, we recommend 68Ga-DOTATATE PET/CT as the preferred modality in pediatric PPGL. 68Ga-DOTATATE PET/CT may evolve as a preferred imaging modality for disease surveillance in VHL.

Corresponding author: Tushar Bandgar, MD, DM, Department of Endocrinology, Seth G.S. Medical College & KEM hospital, Parel, 4000012Mumbai, Maharashtra, India, Phone: (+91) 02224162917, Fax: (022) 24162883, E-mail:

Funding source: Scientific and Engineering Research Board

Award Identifier / Grant number: Grant# SB/SO/HS/041/2013


We acknowledge Vyankatesh Shivane, Neeta Doiphode, and Neelam Jaguste for administrative help in the conduct of the study.

  1. Research funding: This study was funded by the Scientific and Engineering Research Board (SERB), Department of Science and Technology, Government of India (Grant# SB/SO/HS/041/2013).

  2. Author contributions: Study design: Tushar Bandgar. Literature review, data collection, analysis, and drafting of the manuscript: Sanjeet Kumar Jaiswal and Ravikumar shah. Tushar Bandgar, Vijaya Sarathi, and other authors have reviewed, edited, and approved the final manuscript.

  3. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication. The authors have no conflict of interest to disclose.

  4. Informed consent: Considering the retrospective nature of the study waiver of informed consent was obtained for all individuals included in this study.

  5. Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standard.


1. Wyszyńska, T, Cichocka, E, Wieteska‐Klimczak, A, Jobs, K, Januszewicz, P. A single pediatric center experience with 1025 children with hypertension. Acta Paediatr 1992;81:244–6. in Google Scholar

2. Jha, A, Ling, A, Millo, C, Gupta, G, Viana, B, Lin, FI, et al.. Superiority of 68Ga-DOTATAT over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. Eur J Nucl Med Mol Imaging 2018;45:787–97. in Google Scholar

3. Pamporaki, C, Hamplova, B, Peitzsch, M, Prejbisz, A, Beuschlein, F, Timmers, HJLM, et al.. Characteristics of pediatric vs. adult pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 2017;102:1122–32. in Google Scholar

4. Sarathi, V. Characteristics of pediatric pheochromocytoma/paraganglioma. Indian J Endocrinol Metab 2017;21:470–4. in Google Scholar

5. Khadilkar, K, Sarathi, V, Kasaliwal, R, Pandit, R, Goroshi, M, Shivane, V, et al.. Genotype-phenotype correlation in paediatric pheochromocytoma and paraganglioma: a single centre experience from India. J Pediatr Endocrinol Metab 2017;30:575–81. in Google Scholar

6. Jochmanova, I, Abcede, AMT, Guerrero, RJS, Malong, CLP, Wesley, R, Huynh, T, et al.. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents. J Cancer Res Clin Oncol 2020;146:1051–63. in Google Scholar

7. Bausch, B, Wellner, U, Bausch, D, Schiavi, F, Barontini, M, Sanso, G, et al.. Long-term prognosis of patients with pediatric pheochromocytoma. Endocr Relat Cancer 2014;21:17–25. in Google Scholar

8. Taïeb, D, Hicks, RJ, Hindié, E, Guillet, BA, Avram, A, Ghedini, P, et al.. European association of nuclear medicine practice guideline/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2019;46:2112–37. in Google Scholar

9. Lenders, JWM, Duh, Q, Eisenhofer, G, Grebe, SKG, Murad, MH. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol 2014;99:1915–42. in Google Scholar

10. Chang, CA, Pattison, DA, Tothill, RW, Kong, G, Akhurst, TJ, Hicks, RJ, et al.. 68Ga-DOTATATE and 18F-FDG PET/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging 2016;16:22. in Google Scholar

11. Kan, Y, Zhang, S, Wang, W, Liu, J, Yang, J, Wang, Z. 68Ga-somatostatin receptor analogs and 18F-FDG PET/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis. Acta Radiol 2018;59:1466–74. in Google Scholar

12. Gild, ML, Naik, N, Hoang, J, Hsiao, E, McGrath, RT, Sywak, M, et al.. Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomas. Clin Endocrinol 2018;89:139–47. in Google Scholar

13. Janssen, I, Blanchet, EM, Adams, K, Chen, CC, Millo, CM, Herscovitch, P, et al.. Superiority of [68Ga]-DOTATATEPET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res 2015;21:3888–95. in Google Scholar

14. Naji, M, Zhao, C, Welsh, SJ, Meades, R, Win, Z, Ferrarese, A, et al.. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol 2011;13:769–75. in Google Scholar

15. Sharma, P, Thakar, A, Sudhir Suman, KC, Dhull, VS, Singh, H, Naswa, N, et al.. 68Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma. J Nucl Med 2013;54:841–7. in Google Scholar

16. Han, S, Suh, CH, Woo, S, Kim, YJ, Lee, JJ. Performance of 68Ga-DOTA–conjugated somatostatin receptor–targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis. J Nucl Med 2019;60:369–76. in Google Scholar

17. Archier, A, Varoquaux, A, Garrigue, P, Montava, M, Guerin, C, Gabriel, S, et al.. Prospective comparison of 68Ga-DOTATATE and 18F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Eur J Nucl Med Mol Imaging 2016;43:1248–57. in Google Scholar

18. Janssen, I, Chen, CC, Millo, CM, Ling, A, Taieb, D, Lin, FI, et al.. PET/CT comparing 68Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2016;43:1784–91. in Google Scholar

19. Babic, B, Patel, D, Aufforth, R, Assadipour, Y, Sadowski, SM, Quezado, M, et al.. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors. Surgery 2017;161:220–7. in Google Scholar

20. Ilias, I, Meristoudis, G. Functional imaging of paragangliomas with an emphasis on von Hippel – Lindau-associated disease: a mini review. J Kidney Cancer VHL 2017;4:30–6. in Google Scholar

21. Pereira, BD, Nunes, T, Bernardo, AT, César, R, Luiz, HV, Pacak, K, et al.. Review article A clinical roadmap to investigate the genetic basis of pediatric pheochromocytoma: which genes should physicians think about? Int J Endocrinol 2018;2018:8470642. in Google Scholar

22. Shell, J, Tirosh, A, Millo, C, Sadowski, SM, Assadipour, Y, Green, P, et al.. The utility of 68Gallium-DOTATATE PET/CT in the detection of von Hippel-Lindau disease associated tumors. Eur J Radiol 2019;112:130–5. in Google Scholar

23. Sarathi, V, Pandit, R, Jagtap, V, Lila, AR, Bandgar, TR, Menon, PS, et al.. Performance of plasma fractionated free metanephrines by enzyme immunoassay in the diagnosis of pheochromocytoma and paraganglioma. Endocr Pract 2011;17:759–65. in Google Scholar

24. Sarathi, V, Pandit, R, Patil, VK, Lia, AR, Bandgar, TR, Shah, NS. Performance of plasma fractionated free metanephrines by enzyme immunoassay in the diagnosis of pheochromocytoma and paraganglioma in children. Endocr Pract 2012;18:694–9. in Google Scholar

25. Hes, FJ, Höppener, JWM, Lips, CJM. Clinical review 155: pheochromocytoma in von Hippel-Lindau disease. J Clin Endocrinol Metab 2003;88:969–74. in Google Scholar

26. Lam, AK. Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours. Endocr Pathol 2017;28:213–27. in Google Scholar

27. Khadilkar, K, Sarathi, V, Kasaliwal, R, Pandit, R, Goroshi, M, Malhotra, G, et al.. Predictors of malignancy in patients with pheochromocytomas/paragangliomas: Asian Indian experience. Endocr Connect 2016;5:89–97. in Google Scholar

28. Jaiswal, SK, Sarathi, V, Memon, SS, Goroshi, M, Jadhav, S, Prakash, G, et al.. Sympathetic paraganglioma: a single-center experience from western India. Endocr Pract 2019;25:211–9. in Google Scholar

29. Goroshi, M, Jadhav, SS, Sarathi, V, Lila, AR, Patil, VA, Shah, R, et al.. Radiological differentiation of phaeochromocytoma from other malignant adrenal masses: importance of wash-in characteristics on multiphase CECT. Endocr Connect 2019;8:898–905. in Google Scholar

30. Tiwari, A, Shah, N, Sarathi, V, Malhotra, G, Bakshi, G, Prakash, G, et al.. Genetic status determines 18F-FDG uptake in pheochromocytoma/paraganglioma. J Med Imaging Radiat Oncol 2017;61:745–52. in Google Scholar

31. Hofman, MS, Hicks, RJ. Moving beyond “lumpology”: PET/CT imaging of pheochromocytoma and paraganglioma. Clin Cancer Res 2015;38:15–8.10.1158/1078-0432.CCR-15-1073Search in Google Scholar

32. Belhocine, T, Spaepen, K, Dusart, M, Castaigne, C, Muylle, K, Bourgeois, P, et al.. 18FDG PET in oncology: the best and the worst (review). Int J Oncol 2006;28:1249–61. in Google Scholar

33. Jing, H, Li, F, Wang, L, Wang, Z, Li, W, Huo, L, et al.. Comparison of the 68Ga-DOTATATA PET/CT, FDG PET/CT, and MIBG SPECT/CT in the evaluation of suspected primary pheochromocytomas and paragangliomas. Clin Nucl Med 2017;42:525–9. in Google Scholar

34. Janssen, I, Chen, CC, Taieb, D, Patronas, NJ, Millo, CM, Adams, KT, et al.. 68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI. J Nucl Med 2016;57:186–91. in Google Scholar

35. Timmers, HJLM, Chen, CC, Carrasquillo, JA, Whatley, M, Ling, A, Eisenhofer, G, et al.. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst 2012;104:700–8. in Google Scholar

36. Tan, TH, Hussein, Z, Saad, FFA, Shuaib, IL. Diagnostic performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG scintigraphy in mapping metastatic pheochromocytoma and paraganglioma. Nucl Med Mol Imaging 2015;49:143–51. in Google Scholar

37. Sait, S, Pandit-Taskar, N, Modak, S. Failure of MIBG scan to detect metastases in SDHB-mutated pediatric metastatic pheochromocytoma. Pediatr Blood Cancer 2017;64:10. in Google Scholar

Supplementary Material

The online version of this article offers supplementary material (

Received: 2020-06-11
Accepted: 2020-10-15
Published Online: 2020-11-12
Published in Print: 2021-01-27

© 2020 Walter de Gruyter GmbH, Berlin/Boston

Scroll Up Arrow